Premium
The oligomerization domain of p53: Crystal structure of the trigonal form
Author(s) -
Miller Maria,
Lubkowski Jacek,
Mohana Rao J.K.,
Danishefsky Avis T.,
Omichinski James G.,
Sakaguchi Kazuyasu,
Sakamoto Hiroshi,
Appella Ettore,
Gronenborn Angela M.,
Clore G.Marius
Publication year - 1996
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(96)01231-8
Subject(s) - chemistry , crystal structure , trigonal crystal system , domain (mathematical analysis) , crystallography , peptide , stereochemistry , biochemistry , mathematics , mathematical analysis
The structure of the oligomerization domain of the p53 tumor suppressor protein was determined in the trigonal crystal form, using a refined NMR structure as a model. A synthetic peptide comprising residues 319–360 of human p53 crystallized in the space group P3 1 21. There is one biologically relevant tetrameric domain in the crystallographic asymmetric unit. The structure was refined jointly with NMR data, only the third such case (the previous examples being IL‐1β (Shaanan, B., Gronenborn,, A.M., Cohen, G.H., Gilliland, G.L., Veerapandian, B., Davies, D.R. and Clore, G.M. (1992) Science 257, 961–964 [1]) and BPTI (Schiffer, C., Huber, R., Wuthrich, K. and Van Gunsteren, W.F. (1994) J. Mol. Biol. 241, 588–599 [2])), to 2.5 Å resolution with an R factor of 0.207. The distribution of tumor‐derived mutations in the oligomerization region together with structural and biological data suggest a strategy for the design of antitumor therapeutics.